
ARTIVION INC
AORTNYSETrading Snapshot
- Day Range
- $718.92 โ $740.13
- 52-Week Range
- $19.16 โ $48.25
- Volume
- $3.34B
- Avg Volume
- $2.44B
- Shares Outstanding
- 48.5M
- Next Earnings
- Sep 21, 2026
Fundamentals Snapshot
- Annual Revenue
- $441M
- Last Q Revenue
- $126M
- P/E Ratio
- 112.7
- P/S Ratio
- 2.9x
- EPS (TTM)
- $0.24
- Dividend Yield
- โ
Why Investors Own AORT
- โHigh-growth profile โ revenue up +12.2% YoY with expanding US Equity exposure.
- โHealthy economics โ 53% gross margin and 11% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ARTIVION INC
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

Alger Dynamic Opportunities Fund Q2 2026 Portfolio Update
Class A shares of the Alger Dynamic Opportunities Fund outperformed the S&P 500 Index during the second quarter of 2026. Read more here.

Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion, Inc. (AORT) Q2 2026 Earnings Call August 6, 2026 4:30 PM EDTCompany ParticipantsJames Mackin - Chairman, President & CEOLance Berry - EVP,...

Artivion, Inc. 2026 Q2 - Results - Earnings Call Presentation
2026-08-07. The following slide deck was published by Artivion, Inc.
Artivion Affirms FY2026 Sales Guidance of $480.000M-$496.000M vs $486.232M Est
Artivion (NYSE:AORT) affirms FY2026 sales outlook from $480.000 million-$496.000 million to $480.000 million-$496.000 million vs $486.232 million estimate.

Conestoga Micro Cap Composite Q2 2026 Leaders, Laggards, Buys And Sells
Conestoga Micro Cap Composite highlights top performers like Twist Bioscience and key portfolio shifts during Q2 2026. Read the full analysis for more details.

Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results
Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m. ET to discuss the results, followed by a question-and-answer session hosted by Pat Mackin, Chairman, President and Chief Executive Officer of Artivion.